A field study was performed at two police agencies to evaluate the utility and accuracy of five on-site urine analysis drug-testing devices when used to test driving under the influence (DUI) arrestees. The devices evaluated were AccuSign | Rapid Drug Screen | TesTcup-5 | TesTstik ~, and Triage | Standard workplace screening cut-off concentrations were used and samples were tested for marijuana, cocaine and metabolites, amphetamine(s), opiates, and PCP (except opiates 300 ng/mL). Four-hundred arrestees were recruited at each site, informed consent was obtained, and urine specimens were collected from each subject for analysis. Police officers conducted the testing with one device, and trained technicians performed testing with the other four devices. The device used by the officers was rotated. All positive and 5% of the negative samples were confirmed in a laboratory using mass spectrometry. Laboratory cut-off concentrations were 4 ng/mL for carboxy-THC; 50 ng/mL for benzoylecgonine; 100 ng/mL for amphetamines; 50 ng/mL for opiates; and 5 ng/mL for PCP. Approximately one-third (36%) of the subjects tested positive for at least one drug. No randomly selected sample, that tested negative on the devices, tested positive at the laboratory. Based on 800 specimens, the false-negative rate for each device was < 1% for all drug classes. A false positive was defined as testing positive with the device, but the specimen did not contain detectable drug, given the study reporting criteria. For marijuana, benzoylecgonine, and opiates, all devices bad _< 0.25 % false-positive rates. For PCP, the false-positive rates were all < 1.5%. For amphetamine(s), the false-positive rates were all _< 1.75%. These rates were adjusted because study confirmation batteries included methylenedioxyamphetamine, methylenedioxymethamphetamine (MDMA), additional overthe-counter sympathomimetic amines, hydromorphone, and hydrocodone. Without the expanded confirmation battery, false-positive rates approached 4% (Triage) for amphetamines and were _> 2.25% for opiates. Fifty to 90% of the positive amphetamine(s) samples contained MDMA. A similar percentage of the opiate-positive samples contained bydromorphone or hydrocodone. When additional drugs were included in the confirmation testing, it was concluded that the on.site urine analysis drug-testing results were useful in DUI investigations.
Introduction
Numerous studies have demonstrated that impairment by alcohol and/or drug use is a safety concern in the U.S. (1) . Willette and Walsh pointed out that the full impact of drugs on traffic safety was unknown in the early 1980s and, unfortunately, this remains true today (2) . However, data have emerged that provide some insight into the extent of the problem. For example, Williams et al. (3) reported that in a "high risk" sample of 440 young male auto drivers killed in California traffic accidents, 70% of blood specimens contained alcohol, over 40% contained other drugs, 37% contained cannabinoids, and 11% contained cocaine. Soderstrum et al. (4) found that of 1023 patients admitted to The Maryland (Baltimore) Shock and Trauma Unit, 34.7% had very recently used marijuana (i.e., > 3 ng/mL tetrahydrocannabinol in serum) and 33% had blood-alcohol concentrations (BAC) > 0.10% (w/v). The Lund et al. (5) study of 300 paid volunteer truck drivers randomly selected at an interstate weigh station demonstrated that 29% were positive for drugs.
Comparatively little data have been published on the prevalence of drugs in drivers detained by the police for erratic driving. Compton and Anderson (6) reported that the prevalence of drugs in arrested drivers with BACs below 0.10% (w/v) was between 14% and 50%. The most frequently encountered drugs in order of prevalence were marijuana, tranquilizers and sedatives, hallucinogens (PCP), cocaine, amphetamines, and opiates. In the Virginia portion of the study, blood from 788 drivers was tested, and 16% of the samples contained one or more drugs. A six-year California study reviewed by the authors showed annual prevalence rates of 30% to 50% for drugs in arrested drivers (6) . A second California study reviewed by the authors showed that between 14.4% and 23% of the blood samples collected from impaired drivers contained marijuana (6) .
Recently, on-site drug-screening devices have been introduced for urinalysis drug testing (7, 8) . These devices are commercially available, immunoassay based, require no sophisticated instrumentation, and do not require a permanent laboratory or extensively trained personnel. Several studies have been performed to assess the accuracy and reliability of the devices (9) (10) (11) (12) (13) (14) (15) . Brookoff et al. (16) used on-site testing devices to test urine specimens collected from subjects arrested for reckless driving who were not impaired by alcohol. They reported that 58% of the samples tested positive for marijuana (33%), cocaine (13%), or both drugs (12%). In a recent study by Buchan et al. (17, 18) four on-site screening devices were evaluated for use in a law enforcement setting. Prevalence rates for cannabinoids, cocaine/metabolites, and opiates were 15.5%, 13.2%, and 0.7%, respectively, in impaired drivers. All four devices displayed high (96% or higher) levels of specificity (18) . Walsh et al. (17) concluded that routine use of these devices was feasible in law enforcement testing. To further evaluate the potential of using on-site devices in traffic safety, the National Highway Traffic Safety Administration (NHTSA) designed and funded a study in which multiple laboratories evaluated three devices (15) . That study showed consistent results between three laboratories, further documenting the potential of on-site devices for use in highway safety drug-testing applications. As a follow-up of the first study, NHTSA designed a field study with the following objectives: (1) to assess the accuracy and reliability of five current on-site devices; (2) to determine the utility of the on-site testing devices when used at the point of collection; and (3) to determine the accuracy of the devices when used by police ofricers versus trained laboratory analysts (19) . This is the first comprehensive study designed to systematically select the onsite devices, capture a representative sample of driving-underthe influence (DUI) arrestees in two major urban areas, and to evaluate the accuracy of the selected devices when used by actual arresting officers.
Methods

Identification of devices
Several commercially available on-site devices were considered for inclusion in the study. To be seriously considered, the device manufacturer had to be a stable business entity, responsive, and able to provide the devices expeditiously. The manufacturer-recommended procedures were reviewed for simplicity, analysis time, number of reagents, number of testing steps, stability of the test results, and applicability for use by non-technical analysts. Practical issues were considered such as storage requirements, shelf life, special requirements for disposal, and the need for additional supplies and materials. The scientific literature was reviewed to assess the accuracy and reliability of the devices based on published studies. The following devices were selected: AccuSign (Princeton Biomedical Corp., Princeton, N J), OnTrak TesTcup-5 (Roche Diagnostic Systems, Inc., Indianapolis, IN), OnTrak TesTstik (Roche Diagnostic Systems, Inc.), Rapid Drug Screen (American Bio Medica Corp, Ancramdale, NY), and Triage (Biosite Diagnostics, San Diego, CA).
The cut-off concentrations for the devices were consistent with the federal recommendations and are shown in Table I  (20,21 ).
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Journal of Analytical Toxicology, Vol. 26, October 2002 Site selection and on-site testing After considering several potential sites for the study, Houston, TX and Nassau County, NY were selected (19) . Fourhundred subjects were recruited per site. Staff from ISA Associates (ISA) and the Center for Human Toxicology (CHT) trained all officers and the research analysts in the use of the devices. Manufacturers were also encouraged to contact the sites and provide additional training. Data collection began in Houston in October 1998 and was completed in July 1999. In Nassau County, data collection began in November 1998 and was completed in November 1999. Data were collected on Friday and Saturday nights from 10:00 p.m. to 6:00 a.m. All drivers arrested for suspicion of DUI, and processed at each site, were eligible to participate in the project. Written, informed consent was obtained from each participant and subject anonymity was ensured. Every urine sample collected was analyzed using each of the five devices. The sequence in which the devices were used was rotated. For example, if sample 1 was analyzed first with Triage, then TesTcup, AccuSign, Rapid Drug Screen, and TesTstik (in that order), then sample 2 was tested first with TesTcup, then AccuSign, Rapid Drug Screen, TesTstik, and finally with Triage. A police officer always conducted the testing with the first device in the sequence and a research analyst the remaining analyses. The research analysts were trained laboratory technicians familiar with laboratory-based and on-site drug-testing procedures. If a urine sample tested positive for any of the five drug classes on any of the devices, the sample was sent to the CHT for confirmation by mass spectrometry (MS). In addition, 5% of the samples that tested negative on all five devices were also sent for confirmation.
Confirmation testing
Specimens were collected in 60-mL inert plastic collection bottles. Those selected for confirmation were refrigerated and shipped by overnight courier in leak-proof, self-sealing specimen bags. Upon receipt, all specimens were stored frozen. MS confirmations were performed for all drugs presumptively identified by the devices. In addition, the randomly selected negative samples were tested for all drugs in the confirmation analyses. Multipoint calibration curves, containing certified negative urine and at least four calibrators, were generated by fortifying drug-free urine with the target confirmation analytes. Verified negative and positive controls were included in each testing batch. Deuterium-labeled drug analogues were used as internal standards to ensure accurate relative retention time information for qualitative identification and for internal standard quantitation. Liquid chromatography-mass spectrometry (LC-MS) and LC-MS-MS testing was used to supplement the gas chromatography-mass spectrometry (GC-MS) specifically for the identification of additional sympathomimetic amines and opiates (see Results). Each confirmation test was performed on a standard volume of 1.0 mL of urine. Samples testing at concentrations greater than the calibration curve were reported as positive > than the highest calibrator concentration (e.g., 11-nor-A9-tetrahydrocannabinol [THC-COOH] > 250 ng/mL). For THC-COOH confirmation, each urine was hydrolyzed at basic pH, extracted, derivatized, and subjected to GC-MS analysis by negative ion chemical ionization (NCI) with selected ion monitoring (SIM). A cocaine confirmation consisted of testing for parent cocaine and benzoylecgonine (BZE). Each urine was extracted using solid-phase extraction (SPE), the BZE derivatized and subjected to GC-MS analysis for parent cocaine and BZE. The analyses were performed by PCI using SIM. An "amphetamines" confirmation consisted of testing for amphetamine, phentermine, and methamphetamine to a limit of 100 ng/mL. In addition, phenylpropanolamine, ephedrine, pseudoephedrine, and methylenedioxymethamphetamine (MDMA) were qualitatively identified to a detection limit of 200 ng/mL. Initially, urine samples were extracted at basic pH, derivatized, and subjected to GC-MS analysis by PCI with SIM. However, it quickly became apparent that many samples had high concentrations of phenylpropanolamine, ephedrine, pseudoephedrine, and MDMA that adversely affected the chromatography. Therefore, these samples were extracted at basic pH and subjected to LC-MS analysis using positive ion electrospray ionization with SIM. An opiate confirmation was performed for total morphine and codeine. In addition, hydrocodone and hydromorphone were qualitatively identified to a limit of detection of 200 ng/mL. Each urine sample was hydrolyzed enzymatically, extracted at basic pH, derivatized, and subjected to PCI with SIM GC-MS analysis. Many samples contained hydromorphone and hydrocodone. Because of the inherently better chromatographic characteristics for these drugs by LC-MS, these samples were hydrolyzed enzymatically, extracted by SPE, and subjected to LC--MS analysis for the target opiates using positive ion electrospray ionization with SIM. A phencyclidine confirmation consisted of testing for PCP only. Each urine was extracted at basic pH and subjected to GC-MS analysis for PCP. The analysis used PCI with SIM.
Definitions
A "false positive" was recorded when the device indicated a positive test result, but no drug or metabolite was found at a sufficient concentration by MS to explain the result. For example, the Device A result was positive for PCP, and the MS result (using study criteria for PCP identification) was negative.
False-negative results were divided into two categories. False-negative results were assigned to those results in which the device tested negative, but the sample contained the target drug or metabolite at a concentration at or higher than the device screening cut-off. A second category of false-negative results was based on the device testing negative and the sample containing the target drug or metabolite at a concentration at or above the DHHS MS reporting cut-off. Recall that if the sample tested positive on any device it was forwarded for confirmation. Therefore, false-negative results from the other devices could be identified.
The term "unconfirmed positive" was given two definitions. It was used to describe those cases where the device result was positive, but the concentration of drug or metabolite in the urine (as determined by MS) was less than the DHHS cut-off. For example, the result for Device B was positive for PCP and MS quantitation was 10 ng/mL. The drug was present in the urine, but the concentration was less than the DHHS GC-MS reporting cut-off of 25 ng/mL. A second category of "unconfirmed positive" results is shown in Table VI . In this group, the term was used to describe those cases where the device result was positive, but the drug or metabolite detected in the urine (as determined by MS) was not an analyte included in the DHHS list of tested drugs. For example, the result for Device C was positive for opiates and MS result was negative for morphine and codeine, but the sample contained significant concentrations of hydromorphone or hydrocodone.
Results and Discussion
Two hundred and eighty-eight of the 800 specimens collected (36%) tested positive for at least one of the five drug classes with at least one device. MS confirmations were conducted on these specimens and the random sample of specimens that tested negative on all of the devices. The data are summarized in the following tables by drug and reported as false positive, false negative, and unconfirmed positive based on a denominator of 800 cases. Percentages are truncated to two decimal places.
False-positive results
Table II presents the false-positive results. As indicated, these data include those cases in which the device's positive result could not be confirmed using the study MS confirmation criteria.
One hundred and seventy-two samples tested positive on one or more of the devices for THC-COOH. Only two of these samples were negative by MS. Both gave false-positive results with AccuSign (0.25%), and one (0.12%) produced a false-positive result with Rapid Drug Screen. One hundred and twentyfour samples tested positive on one or more of the on-site devices for BZE. Only one of these samples tested negative by MS. That sample produced a false-positive result with both AccuSign and Rapid Drug Screen. Thirty-nine samples tested positive on one or more of the devices for the amphetamines. Only six had measurable concentrations of amphetamine, methamphetamine, or phentermine (the target analytes) by MS. However, the false-positive rates shown in the table were adjusted because many of the samples contained MDMA (see unconfirmed positive results). Thirty-eight samples tested positive on one or more of the devices for opiates. Nineteen contained measurable concentrations of morphine or codeine by MS. However, hydrocodone and hydromorphone were detected in nearly all of the opiate positive samples, which explained many of the positive results (see unconfirmed-positive rates). Thirty-eight samples tested positive for PCP on one or more of the on-site devices, and 23 contained measurable concentrations of PCP by MS. Four samples that were not confirmed by MS tested positive with all of the devices, and a fifth tested positive with four of the five devices.
False-negative results
False-negative test results are important because they represent the DUI arrestees who had significant concentrations of drug in their urine, but who would not have been identified as drug users. In addition, these subjects may have avoided prosecution for DUI because of the lack of chemical evidence of their drug use. Tables III and IV present the two categories of false-negative results. The results in Table III are based on the device and DHHS screening cut-off concentrations and the resuits in Table IV are based on the DHHS MS-reporting cut-off.
From the 5% randomly selected negative samples, we identified no false-negative results.
The samples that tested negative on one or more devices, but contained more than 50 ng/mL of THC-COOH by MS are shown in Table III . Those samples tested negative on one or more devices that contained more than 15 ng/mL of THC-COOH by MS are shown in Table IV . Using the 15 ng/mL reporting criterion, the false-negative rates were, predictably, higher. There did not appear to be a pattern that certain samples were not detected by certain devices, because no sample in either category tested falsely negative on all devices. The false-negative rates for BZE using the 300-ng/mL screen cut-off are shown in Table III . Table IV shows that additional samples tested negative on the devices that contained more than 150 ng/mL of BZE. There were too few false-negative results using either criterion to determine if there was a pattern in the discrepancies. There were no falsenegative amphetamine results using either the device/DHHS screening or DHHS MS reporting criteria. For opiates, one sample tested negative using TesTcup (0.12%), but it was a false-negative result compared with either the screening or MS criteria. No false-negative errors were found for opiates with the other four devices. Two samples tested negative using TesTcup and one with Rapid Drug Screen that were false-negative PeP results using either the DHHS screening or MS reporting criteria. No false-negative PeP errors were reported from the other devices.
Unconfirmed-positive results--based on analytical cut-off
A number of studies have been published that assessed the accuracy and reliability of on-site drug screening devices (8, 10, 12, 15, 18, 22, 23) . The basic design of those studies was similar to the study reported here. On-site test results were compared with results obtained from one or more alternate methods. However, unlike the data in Tables III and IV, these comparisons were usually made based on laboratory results using the DHHS testing and reporting guidelines. The "unconfirmed positive" results presented in Table V were defined as results in which the device(s) tested positive, but compared with the DHHS MS guidelines, the sample(s) would have been reported negative because they contained an MS-measured drug concentration less than the reporting standards. This is an important category of results because it represents those DUI arrestees who had drugs in their urine, but who would have been reported as drug free. It also is the category to which many of the false-positive results in previous studies could have been assigned.
Of the 172 samples that tested positive for THC-COOH, only two were negative by study MS criteria. However, as shown in the table, several had MS-measured concentrations of THe- COOH that were less than the 15 ng/mL DHHS standard. There were seven samples in this category that produced a positive test result with all of the devices. The mean THC-COOH concentration of these seven samples was 10.33 ng/mL, and only one contained less than 10 ng/mL of THC-COOH. Lowering the current DHHS cut-off even by 1/2 to 7.5 ng/mL would result in the following unconfirmed positive percentages: Triage 0.25%; TesTcup 0.25%; AccuSign 0.25%; Rapid Drug Screen 0.12%; and TesTstik 0.12%. Of the 124 samples that tested positive for BZE, only one was negative by MS (Table II) . However, 14 had MS concentrations of BZE that were less than the 150 ng/mL. There were three samples that produced a positive result on all devices that contained less than 150 ng/mL of BZE. The mean concentration of all of the unconfirmed positive samples was 86.57 ng/mL. Therefore, lowering the current DHHS cut-off by just 1/2 to 75 ng/mL for BZE would result in the following unconfirmed positive rates: Triage, TesTcup, and TesTstik--0.00% and AccuSign and Rapid Drug Screen--0.00%. Of the 39 samples that tested positive for amphetamines (on one or more devices), only one produced a positive result on all devices that had a concentration of amphetamine less than the 500 ng/mL DHHS confirmation standard. A second sample contained more than 1000 ng/mL of phentermine, tested positive on all of the devices, and could have been classified as an unconfirmed false-positive result because the DHHS program does not include phentermine confirmation. Only Rapid Drug Screen published their device cross-reactivity to phentermine (1%).
Of the 38 samples that tested positive for opiates (on one or more devices), 19 contained measurable concentrations of morphine or codeine by MS. However, three had concentrations of morphine and/or codeine lower than the 300 ng/mL DHHS GC-MS standard (Table V) . One sample tested positive on all of the devices, but contained only 115 ng/mL of codeine. 1Mo addi- 
Unconfirmed-positive results--based on tested drugs
As discussed, a major consideration in evaluating the accuracy and reliability of the devices was the selection of a comparison standard. Usually, the onsite test results have been compared to laboratory results using the DHHS testing guidelines. In this section, "unconfirmed positive" results are defined as results in which the device(s) tested positive, but compared with the DHHS criteria, the sample(s) would have been reported negative because they did not contain detectable concentrations of the DHHS target drugs. Again, this is an important category of samples because these DUI arrestees (who had drugs in their urine) would have been reported as drug free using the federal standards. This is also the category to which many of the false-positive results in previous studies should have been assign. Table VI presents the percentage of unconfirmed positive results based on tested drugs.
Because the target analytes for THC-COOH, cocaine, and PCP in the devices and the GC-MS confirmation are the same, no differences were observed between the unconfirmed-positive results based on tested drugs (Table VI) and the false-positive rates (Table II) doephedrine, or ephedrine. The published cross-reactivities of the devices to these over-the-counter drugs was quite low and not a likely explanation for the positive test results. However, this explanation cannot be ruled out because only qualitative MS analyses were performed for these drugs. All but one the Triage and two of the TesTcup, AccuSign, Rapid Drug Screen, and TesTstik unconfirmed opiate positive samples shown in Table VI contained both hydromorphone and hydrocodone at concentrations > 200 ng/mL. The crossreactivities of the devices to hydromorphone were 75%, Triage; 43%, TesTcup; 50%, AccuSign; and 43%, TesTstik. (Rapid Drug Screen's hydromorphone cross-reactivity was not published by the manufacturer.) The cross-reactivity of the devices to hydrocodone was as follows: 60%, TesTcup; 60%, AccuSign; 6%, Rapid Drug Screen; and 38%, TesTstik. (Triage's hydrocodone cross-reactivity was not published by the manufacturer.) The presence of hydromorphone and hydrocodone provided a likely explanation for the positive on-site device test results for several reasons. Both hydromorphone and hydrocodone were detected in all samples. Therefore, the immunoresponse of each sample was equal to the combined effects of both drugs. Also, in many of the samples the estimated drug concentrations (based on their MS response relative to morphine and codeine) were quite high. Finally, (with two exceptions) all the unconfirmed-positive opiate samples that contained hydromorphone and/or hydrocodone tested positive on all of the devices.
Comparison of officer test results and research analyst test results
Results from the analysis conducted by the officers were compared to those conducted by the research analysts. Table VII presents the results of that comparison. Of the 4000 drug screens performed (5 devices x 800 samples), there were 47 screens in which i device's results were in error and the other 4 devices performed accurately. Twenty-seven of those errors occurred when the research analysts performed the analysis, and 20 occurred when the officers performed the analysis. When the data were normalized to the number of analyses performed by the research analysts and by the officers, the error rate for the research analysts was 0.8% (27/3200) and that for the officers was 2.5% (20/800). Dramatic differences were found in the error rates across devices. As Table VII indicates, officers had a considerably higher percentage of errors using Triage, AccuSign, and Rapid Drug Screen than the research analysts.
Conclusions
A number of patterns emerged from comparing the on-site device results with those from the MS confirmations. First, the devices generated relatively few false-positive results, particularly for THC-COOH, PCP, and BZE. However, the unconfirmedpositive rates were higher particularly for amphetamines and opiates. These rates were attributable largely to the presence of drugs other than the target DHHS analyte(s). Rates for THC-COOH, cocaine/BZE and PCP were consistent with those expected using instrumented immunoassay screening. However, when testing for amphetamines there were 17 cases in which all 5 devices were positive, but no methamphetamine or amphetamine was detected by MS. Consequently, the unconfirmed-positive rates ranged from 2.12 to 3.75%. A similar pattern was seen with the opiates where rates varied from 2.25% to 2.37%. When the data were corrected for the presence of MDMA, hydromorphone, and hydrocodone, the false-positive rates for amphetamines and opiates fell to less than 2% and less than 0.3%, respectively. These lower rates were consistent with those anticipated using instrumented immunoassays. However, the adjusted rates clearly indicate that the confirmation battery for opiates and amphetamines needs to be expanded to be effective in DUI investigations.
The unconfirmed-positive rates based on drug concentration, were less than 1.37%. Rates between devices were essentially equal for THC-COOH, amphetamines, opiates, and PCP. When testing for BZE, however, AccuSign and Rapid Drug Screen had higher rates than the other devices. Reducing the DHHS confirmation cut-off by one half reduced the unconfirmed-positive rate for THC-COOH to less than 0.25% for all devices. For BZE testing, decreasing the confirmation cut-off reduced the unconfirmed-positive rate to 0.0% for three of the five devices and to 0.75% for AccuSign and Rapid Drug Screen. These results indicate that lowering the DHHS MS confirmation cut-offs would substantially improve the utility of the devices.
When the false-negative results were assessed based on the immunoassay screening cut-off, they were quite rare and the devices compared favorably across drug classes. Only the falsenegative rate for THC-COOH testing with Rapid Drug Screen exceeded 0.25%. The devices also compared favorably across drug classes when the false-negative rates were calculated based on the DHHS MS reporting cut-offs. False-negative rates were less than 0.87% for all of the devices and all drug classes. Only the false-negative results for THC-COOH exceeded 0.50%, and then only for TesTcup and TesTstik.
The most significant findings from this study were that the devices had few false-negative and false-positive results. Therefore, they effectively identified DUI arrestees with drugs in their urine.
A unique feature of this study was that it was a field test. Previous studies of the on-site devices have been primarily laboratory based. This study provided an opportunity to examine the performance of the devices at the site of collection and when used by law enforcement personnel. The overall error rates for trained laboratory technicians and the officers were low: 0.8% for technicians and 2.5% for officers. Although the rates were low, the error rate of the officers was three times that of the research analysts. This finding suggests that additional training is needed if the on-site devices are to be used routinely by law enforcement officers.
It should be noted that detecting a drug or drug metabolite in urine does not indicate that the individual is under the influence of the drug/metabolite. Detection merely provides objective chemical evidence of the drug/metabolite's presence and is only part of a thorough DUI investigation.
